- Home
- CHWY vs PCVX Comparison
CHWY vs PCVX Comparison
Compare CHWY & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHWY | PCVX |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 7.0B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CHWY | PCVX |
|---|---|---|
| Price | $24.50 | $62.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 24 | 4 |
| Target Price | $43.52 | ★ $88.25 |
| AVG Volume (30 Days) | ★ 6.5M | 915.3K |
| Earning Date | 06-10-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $12,601,500,000.00 | N/A |
| Revenue This Year | $10.70 | N/A |
| Revenue Next Year | $7.84 | N/A |
| P/E Ratio | $106.52 | ★ N/A |
| Revenue Growth | ★ 6.24 | N/A |
| 52 Week Low | $17.40 | $29.87 |
| 52 Week High | $43.50 | $65.00 |
Technical Indicators
Market Signals| Indicator | CHWY | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 63.99 | 62.58 |
| Support Level | $22.90 | $52.18 |
| Resistance Level | $27.77 | $65.00 |
| Average True Range (ATR) | 0.80 | 2.23 |
| MACD | 0.09 | 0.40 |
| Stochastic Oscillator | 84.27 | 89.43 |
Price Performance
Historical ComparisonAbout CHWY Chewy Inc.
Founded in 2011, Chewy is a leading e-commerce retailer of pet food, toys, supplies, and medications in North America. The firm offers a comprehensive selection of proprietary and third-party brands, anchored by its highly sticky autoship subscription program, which drives over 83% of its sales. Beyond core retail, Chewy is expanding into high-margin revenue streams, including its retail media network (Chewy Ads), specialized veterinary healthcare software, and brick-and-mortar veterinary clinics to further integrate customers into the Chewy ecosystem.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.